With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...

When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients ...

Dan Crippen was the director of the Congressional Budget Office from 1999 to 2003. In its first report on the 340B drug discount program's effect on the budget, the Congressional Budget Office ...

Effective compliance now spans transaction eligibility, OPAIS synchronization, Medicaid exclusion validation, cost-report ...

Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...

Nevada hospitals and clinics face challenges as drug manufacturers restrict access to a federal discount drug program, ...

On December 29, 2025—just three days before the 340B Rebate Model Pilot Program (the Rebate Program) was set to begin—the U.S. District Court for the District of Maine issued an order granting a ...

Minnesota's 340B drug discount program faces scrutiny as small clinics struggle and large hospitals profit, sparking ...

It’s no secret that for working families, the cost of healthcare has spiraled out of control. But much less known is the degree to which the 340B Drug Pricing Program, built to help the patients who ...

Pending legislation to expand providers’ access to discounted drugs has sparked strong lobbying campaigns for and against the proposal.